Erratum: Focal segmental glomerulosclerosis(Clin J Am Soc Nephrol (2017),12,502-517, 10.2215/CJN.05960616);Focal segmental glomerulosclerosis

Clinical Journal of the American Society of Nephrology

Volumn 12, Issue 3, 2017, Pages 502-517

  Rosenberg, Avi Z ^a,b   Kopp, Jeffrey B ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Alleles; Biopsy; Body Size; Fluorescent Antibody Technique; Focal Segmental; Genetic Testing; Glomerulosclerosis; Humans; Hypertrophy; Immunosuppression; Kidney; Kidney Diseases; Kidney Glomerulus; Kidney transplantation; Microscopy Electron; Mutation; Nephrotic syndrome; Penetrance; Podocytes; Segmental; Workload

Indexed keywords

2 ACETYLAMINO 2 DEOXY MANNOPYRANOSE; ABATACEPT; ADALIMUMAB; APOLIPOPROTEIN; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHLORAMBUCIL; CHLORTALIDONE; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EXPORTIN 5; FRESOLIMUMAB; GLUCOCORTICOID; LEVAMISOLE; LOSMAPIMOD; MIZORIBINE; MYCOPHENOLATE MOFETIL; NEPHRIN; PIRFENIDONE; PREDNISONE; RAMIPRIL; SPARSENTAN; SYNAPTOPODIN; TACROLIMUS; TELMISARTAN; TRANSCRIPTION FACTOR PAX2; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; UNINDEXED DRUG; WT1 PROTEIN; ANGIOTENSIN RECEPTOR ANTAGONIST; APOL1 PROTEIN, HUMAN; APOLIPOPROTEIN L1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CREATININE CLEARANCE; DNA REPAIR; ELECTRON MICROSCOPY; EXTRACHROMOSOMAL INHERITANCE; FOCAL GLOMERULOSCLEROSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC VARIABILITY; GLOBAL DISEASE BURDEN; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOTHERAPY; KIDNEY BIOPSY; NONHUMAN; NUCLEOCYTOPLASMIC TRANSPORT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; COMBINATION DRUG THERAPY; COMPLICATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOLOGY;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; APOLIPOPROTEIN L1; CALCINEURIN INHIBITORS; DRUG THERAPY, COMBINATION; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GLUCOCORTICOIDS; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 85021735573     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.12071018     Document Type: Erratum

References (139)

1. Chen YM, Liapis H: Focal segmental glomerulosclerosis: Molecular genetics and targeted therapies. BMC Nephrol 16: 101, 2015
2. D’Agati VD, Kaskel FJ, Falk RJ: Focal segmental glomerulosclerosis. N Engl J Med 365: 2398–2411, 2011
3. Gbadegesin R, Lavin P, Foreman J, Winn M: Pathogenesis and therapy of focal segmental glomerulosclerosis: An update. Pediatr Nephrol 26: 1001–1015, 2011
4. Sethi S, Glassock RJ, Fervenza FC: Focal segmental glomerulosclerosis: Towards a better understanding for the practicing nephrologist. Nephrol Dial Transplant 30: 375–384, 2015
5. D’Agati VD: Pathobiology of focal segmental glomerulosclerosis: New developments. Curr Opin Nephrol Hypertens 21: 243–250, 2012
6. Fogo AB: Causes and pathogenesis of focal segmental glomerulosclerosis. Nat Rev Nephrol 11: 76–87, 2015
7. Mondini A, Messa P, Rastaldi MP: The sclerosing glomerulus in mice and man: Novel insights. Curr Opin Nephrol Hypertens 23: 239–244, 2014
8. Schell C, Huber TB: New players in the pathogenesis of focal segmental glomerulosclerosis. Nephrol Dial Transplant 27: 3406–3412, 2012
9. Kiffel J, Rahimzada Y, Trachtman H: Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients. Adv Chronic Kidney Dis 18: 332–338, 2011
10. Kronbichler A, Leierer J, Oh J, Meijers B, Shin JI: Immunologic changes implicated in the pathogenesis of focal segmental glomerulosclerosis. BioMed Res Int 2016: 2150451, 2016
11. Sethna CB, Gipson DS: Treatment of FSGS in children. Adv Chronic Kidney Dis 21: 194–199, 2014
12. Coppo R: Different targets for treating focal segmental glomerular sclerosis. Contrib Nephrol 181: 84–90, 2013
13. Korbet SM: Treatment of primary FSGS in adults. J AmSoc Nephrol 23: 1769–1776, 2012
14. Meyrier A: Focal and segmental glomerulosclerosis: Multiple pathways are involved. Semin Nephrol 31: 326–332, 2011
15. McGrogan A, Franssen CF, de Vries CS: The incidence of primary glomerulonephritis worldwide: A systematic review of the literature. Nephrol Dial Transplant 26: 414–430, 2011
16. Briganti EM, Dowling J, Finlay M, Hill PA, Jones CL, Kincaid-Smith PS, Sinclair R, McNeil JJ, Atkins RC: The incidence of biopsy-proven glomerulonephritis in Australia. Nephrol Dial Transplant 16: 1364–1367, 2001
17. Sim JJ, Batech M, Hever A, Harrison TN, Avelar T, Kanter MH, Jacobsen SJ: Distribution of biopsy-proven presumed primary glomerulonephropathies in 2000-2011 among a racially and ethnically diverse US population. Am J Kidney Dis 68: 533–544, 2016
18. Kitiyakara C, Eggers P, Kopp JB: Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 44: 815–825, 2004
19. Asinobi AO, Ademola AD, Okolo CA, Yaria JO: Trends in the histopathology of childhood nephrotic syndrome in Ibadan Nigeria: Preponderance of idiopathic focal segmental glomerulosclerosis. BMC Nephrol 16: 213, 2015
20. D’Agati VD, Fogo AB, Bruijn JA, Jennette JC: Pathologic classification of focal segmental glomerulosclerosis: A working proposal. Am J Kidney Dis 43: 368–382, 2004
21. Silverstein DM, Craver R: Presenting features and short-term outcome according to pathologic variant in childhood primary focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2: 700–707, 2007
22. Thomas DB, Franceschini N, Hogan SL, Ten Holder S, Jennette CE, Falk RJ, Jennette JC: Clinical andpathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 69: 920–926, 2006
23. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR: Association of trypa-nolytic ApoL1 variants with kidney disease in African Americans. Science 329: 841–845, 2010
24. Kopp JB: Focal segmental glomerulosclerosis and collapsing glomerulopathy syndromes. In: Essentials of Chronic Kidney Disease, edited by Fadem SZ, Hauppauge, Nova Science Publishers, 2015
25. Fahr T: Pathologische anatomie des morbus brightii. In: Hand-buch der Speziellen Pathologischen Anatomie und Histologie, edited by Henke F, Lubarsch O, Berlin, Springer, 1925
26. Rich AR: A hitherto undescribed vulnerability of the juxtame-dullary glomeruli in lipoid nephrosis. Bull Johns Hopkins Hosp 100: 173–186, 1957
27. Corwin HL, Schwartz MM, Lewis EJ: The importance of sample size in the interpretation of the renal biopsy. Am J Nephrol 8: 85– 89, 1988
28. Schachter AD: Computational simulation of renal biopsy accuracy in focal segmental glomerulosclerosis. Pediatr Nephrol 21: 953–957, 2006
29. Fogo A, Glick AD, Horn SL, Horn RG: Is focal segmental glomerulosclerosis really focal? Distribution of lesions in adults and children. Kidney Int 47: 1690–1696, 1995
30. Wagrowska-Danilewicz M, Danilewicz M: [Synaptopodin im-munoexpression in steroid-responsive and steroid-resistant minimal change disease and focal segmental glomerulo-sclerosis]. Nefrologia 27: 710–715, 2007
31. Giannico G, Yang H, Neilson EG, Fogo AB: Dystroglycan in the diagnosis of FSGS. Clin J Am Soc Nephrol 4: 1747–1753, 2009
32. Meehan SM, Chang A, Gibson IW, Kim L, Kambham N, Laszik Z: A study of interobserver reproducibility of morphologic lesions of focal segmental glomerulosclerosis. Virchows Arch 462: 229–237, 2013
33. Han MH, Kim YJ: Practical application of columbia classification for focal segmental glomerulosclerosis. BioMed Res Int 2016: 9375753, 2016
34. Schwartz MM, Korbet SM: Primary focal segmental glomerulosclerosis: Pathology, histological variants, and pathogenesis. Am J Kidney Dis 22: 874–883, 1993
35. Stokes MB, D’Agati VD: Morphologic variants of focal segmental glomerulosclerosis and their significance. Adv Chronic Kidney Dis 21: 400–407, 2014
36. Zhong Y, Xu F, Li X, Chen H, Liang S, Zhu X, Liu Z, Zeng C: The evolution of morphological variants of focal segmental glomerulosclerosis: A repeat biopsy-based observation. Nephrol Dial Transplant 31: 87–95, 2016
37. Strassheim D, Renner B, Panzer S, Fuquay R, Kulik L, Ljubanovićc D, Holers VM, Thurman JM: IgM contributes to glomerular injury in FSGS. J Am Soc Nephrol 24: 393–406, 2013
38. Deegens JK, Dijkman HB, Borm GF, Steenbergen EJ, van den Berg JG, Weening JJ, Wetzels JF: Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney Int 74: 1568–1576, 2008
39. Wiggins RC: The spectrum of podocytopathies: A unifying view of glomerular diseases. Kidney Int 71: 1205–1214, 2007
40. Fukuda A, Chowdhury MA, Venkatareddy MP, Wang SQ, Nishizono R, Suzuki T, Wickman LT, Wiggins JE, Muchayi T, Fingar D, Shedden KA, Inoki K, Wiggins RC: Growth-dependent podocyte failure causes glomerulosclerosis. J Am Soc Nephrol 23: 1351–1363, 2012
41. Kriz W, Gretz N, Lemley KV: Progression of glomerular diseases: Is the podocyte the culprit? Kidney Int 54: 687–697, 1998
42. Kriz W, Lemley KV: A potential role for mechanical forces in the detachment of podocytes and the progression of CKD. J AmSoc Nephrol 26: 258–269, 2015
43. Gallon L, Leventhal J, Skaro A, Kanwar Y, Alvarado A: Resolution of recurrent focal segmental glomerulosclerosis after retrans-plantation. N Engl J Med 366: 1648–1649, 2012
44. Komatsu K, Frohlich ED, Ono H, Ono Y, Numabe A, Willis GW: Glomerular dynamics and morphology of aged spontaneously hypertensive rats. Effects of angiotensin-converting enzyme inhibition. Hypertension 25: 207–213, 1995
45. Savin VJ, Sharma M, Zhou J, Gennochi D, Fields T, Sharma R, McCarthy ET, Srivastava T, Domen J, Tormo A, Gauchat JF: Renal and hematological effects of CLCF-1, a B-Cell-stimulating cytokine of the IL-6 family. J Immunol Res 2015: 714964, 2015
46. Lopez-Hellin J, Cantarell C, Jimeno L, Sanchez-Fructuoso A, Puig-Gay N, Guirado L, Vilarino N, Gonzalez-Roncero FM, Mazuecos A, Lauzurica R, Burgos D, Plumed JS, Jacobs-Cacha C, Jimenez C, Fernandez A, Fernandez-Alvarez P, Torregrosa V, Nieto JL, Meseguer A, Alonso A; GREAT Study Group: A form of apolipoprotein a-I is found specifically in relapses of focal segmental glomerulosclerosis following transplantation. Am J Transplant 13: 493–500, 2013
47. Delville M, Sigdel TK, Wei C, Li J, Hsieh SC, Fornoni A, Burke GW, Bruneval P, Naesens M, Jackson A, Alachkar N, Canaud G, Legendre C, Anglicheau D, Reiser J, Sarwal MM: A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med 6: 256ra136, 2014
48. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J: Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17: 952–960, 2011
49. Maas RJ, Deegens JK, Wetzels JF: Serum suPAR in patients with FSGS: Trash or treasure? Pediatr Nephrol 28: 1041–1048, 2013
50. Spinale JM, Mariani LH, Kapoor S, Zhang J, Weyant R, Song PX, Wong HN, Troost JP, Gadegbeku CA, Gipson DS, Kretzler M, Nihalani D, Holzman LB; Nephrotic Syndrome Study Network: A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease. Kidney Int 87: 564–574, 2015
51. Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, Chu R, Chen Y, Zhao MH: Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int 84: 366–372, 2013
52. Peng Z, Mao J, Chen X, Cai F, Gu W, Fu H, Shen H, Wang J, Jin X, Zhu X, Liu A, Shu Q, Du L: Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children. Pediatr Nephrol 30: 301–307, 2015
53. Maas RJ, Wetzels JF, Deegens JK: Serum-solubleurokinasereceptor concentration in primary FSGS. Kidney Int 81: 1043–1044, 2012
54. Wada T, Nangaku M: A circulating permeability factor in focal segmental glomerulosclerosis: The hunt continues. Clin Kidney J 8: 708–715, 2015
55. Harris JJ, McCarthy HJ, Ni L, Wherlock M, Kang H, Wetzels JF, Welsh GI, Saleem MA: Activeproteases in nephrotic plasma lead to a podocin-dependent phosphorylation of VASP in podocytes via protease activated receptor-1. J Pathol 229: 660–671, 2013
56. Kachurina N, Chung CF, Benderoff E, Babayeva S, Bitzan M, Goodyer PR, Kitzler T, Matar D, Cybulsky AV, Alachkar N, Torban E: Novel unbiased assay for circulating podocyte-toxic factors associated with recurrent focal segmental glomerulosclerosis. Am J Physiol Renal Physiol 310: F1148–F1156, 2015
57. Mallipattu SK, He JC: The podocyte as a direct target for treatment of glomerular disease? Am J Physiol Renal Physiol 311: F46–F51, 2016
58. Mallipattu SK, Guo Y, Revelo MP, Roa-Pena L, Miller T, Ling J, Shankland SJ, Bialkowska AB, Ly V, Estrada C, Jain MK, Lu Y, Ma’ayan A, Mehrotra A, Yacoub R, Nord EP, Woroniecki RP, Yang VW, He JC: Kruppel-like factor 15 mediates glucocorticoid-induced restoration of podocyte differentiation markers. J Am Soc Nephrol 28: 166–184, 2016
59. Laurin LP, Gasim AM, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Foster BJ, Nachman PH: Treatment with glucocorticoids or calcineurin inhibitors in primary FSGS. Clin J Am Soc Nephrol 11: 386–394, 2016
60. Canaud G, Dion D, Zuber J, Gubler MC, Sberro R, Thervet E, Snanoudj R, Charbit M, Salomon R, Martinez F, Legendre C, Noel LH, Niaudet P: Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: Course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS). Nephrol Dial Transplant 25: 1321–1328, 2010
61. Canaud G, Zuber J, Sberro R, Royale V, Anglicheau D, Snanoudj R, Gaha K, Thervet E, Lefrère F, Cavazzana-Calvo M, Noël LH, Méjean A, Legendre C, Martinez F: Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: A pilot study. Am J Transplant 9: 1081–1086, 2009
62. Barisoni L, Schnaper HW, Kopp JB: A proposed taxonomy for the podocytopathies: A reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol 2: 529–542, 2007
63. Brenner BM, Mackenzie HS: Nephron mass as a risk factor for progression of renal disease. Kidney Int Suppl 63: S124–S127, 1997
64. Morgan C, Al-Aklabi M, Garcia Guerra G: Chronic kidney disease in congenital heart disease patients: Anarrativereviewof evidence. Can J Kidney Health Dis 2: 27, 2015
65. Aygun B, Mortier NA, Smeltzer MP, Hankins JS, Ware RE: Glomerular hyperfiltration and albuminuria in children with sickle cell anemia. Pediatr Nephrol 26: 1285–1290, 2011
66. Wickman C, Kramer H: Obesity and kidney disease: Potential mechanisms. Semin Nephrol 33: 14–22, 2013
67. Herlitz LC, Markowitz GS, Farris AB, Schwimmer JA, Stokes MB, Kunis C, Colvin RB, D’Agati VD: Development of focal segmental glomerulosclerosis after anabolic steroid abuse. J AmSoc Nephrol 21: 163–172, 2010
68. Hanly PJ, Ahmed SB: Sleep apnea and the kidney: Is sleep apnea a risk factor for chronic kidney disease? Chest 146: 1114– 1122, 2014
69. Ikezumi Y, Suzuki T, Karasawa T, Yamada T, Hasegawa H, Nishimura H, Uchiyama M: Low birthweight and premature birth are risk factors for podocytopenia and focal segmental glomerulosclerosis. Am J Nephrol 38: 149–157, 2013
70. Kriz W, Lemley KV: Mechanical challenges to the glomerular filtration barrier: Adaptations and pathway to sclerosis [pub-lished online ahead of print March 23, 2016]. Pediatr Nephrol doi:10.1007/s00467-016-3358-9
71. Gasser DL, Winkler CA, Peng M, An P, McKenzie LM, Kirk GD, Shi Y, Xie LX, Marbois BN, Clarke CF, Kopp JB: Focal segmental glomerulosclerosis is associated with a PDSS2 haplotype and, independently, with a decreased content of coenzyme Q10. Am J Physiol Renal Physiol 305: F1228–F1238, 2013
72. Yu H, Artomov M, Brähler S, Stander MC, Shamsan G, Sampson MG, White JM, Kretzler M, Miner JH, Jain S, Winkler CA, Mitra RD, Kopp JB, Daly MJ, Shaw AS: A role for genetic susceptibility in sporadic focal segmental glomerulosclerosis. J Clin Invest 126: 1603, 2016
73. Gast C, Pengelly RJ, Lyon M, Bunyan DJ, Seaby EG, Graham N, Venkat-Raman G, Ennis S: Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis. Nephrol Dial Transplant 31: 961–970, 2016
74. Ozaltin F, Ibsirlioglu T, Taskiran EZ, Baydar DE, Kaymaz F, Buyukcelik M, Kilic BD, Balat A, Iatropoulos P, Asan E, Akarsu NA, Schaefer F, Yilmaz E, Bakkaloglu A; PodoNet Consortium: Disruption of PTPRO causes childhood-onset nephrotic syndrome. Am J Hum Genet 89: 139–147, 2011
75. Sadowski CE, Lovric S, Ashraf S, Pabst WL, Gee HY, Kohl S, Engelmann S, Vega-Warner V, Fang H, Halbritter J, Somers MJ, Tan W, Shril S, Fessi I, Lifton RP, Bockenhauer D, El-Desoky S, Kari JA, Zenker M, Kemper MJ, Mueller D, Fathy HM, Soliman NA, Hildebrandt F; SRNS Study Group: A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J AmSoc Nephrol 26: 1279–1289, 2015
76. Trautmann A, Bodria M, Ozaltin F, Gheisari A, Melk A, Azocar M, Anarat A, Caliskan S, Emma F, Gellermann J, Oh J, Baskin E, Ksiazek J, Remuzzi G, Erdogan O, Akman S, Dusek J, Davitaia T, Özkaya O, Papachristou F, Firszt-Adamczyk A, Urasinski T, Testa S, Krmar RT, Hyla-Klekot L, Pasini A, Özcakar ZB, Sallay P, Cakar N, Galanti M, Terzic J, Aoun B, Caldas Afonso A, Szymanik-Grzelak H, Lipska BS, Schnaidt S, Schaefer F; PodoNet Consortium: Spectrum of steroid-resistant and congenital nephrotic syndrome in children: The PodoNet registry cohort. Clin J Am Soc Nephrol 10: 592–600, 2015
77. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, McGuire AL, Nussbaum RL, O’Daniel JM, Ormond KE, Rehm HL, Watson MS, Williams MS, Biesecker LG; American College of Medical Genetics and Genomics: ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 15: 565–574, 2013
78. Büscher AK, Beck BB, Melk A, Hoefele J, Kranz B, Bamborschke D, Baig S, Lange-Sperandio B, Jungraithmayr T, Weber LT, Kemper MJ, Tönshoff B, Hoyer PF, Konrad M, Weber S; German Pediatric Nephrology Association (GPN): Rapid response to cyclosporin A and favorable renal outcome in nongenetic versus genetic steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 11: 245–253, 2016
79. Meehan SM, Kim L, Chang A: A spectrum of morphologic lesions of focal segmental glomerulosclerosis by Columbia criteria in human immunodeficiency virus infection. Virchows Arch 460: 429–435, 2012
80. Marras D, Bruggeman LA, Gao F, Tanji N, Mansukhani MM, Cara A, Ross MD, Gusella GL, Benson G, D’Agati VD, Hahn BH, Klotman ME, Klotman PE: Replication and compartmentaliza-tion of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med 8: 522–526, 2002
81. Husain M, Gusella GL, Klotman ME, Gelman IH, Ross MD, Schwartz EJ, Cara A, Klotman PE: HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J Am Soc Nephrol 13: 1806–1815, 2002
82. Hiramatsu N, Hiromura K, Shigehara T, Kuroiwa T, Ideura H, Sakurai N, Takeuchi S, Tomioka M, Ikeuchi H, Kaneko Y, Ueki K, Kopp JB, Nojima Y: Angiotensin II type 1 receptor blockade inhibits the development and progression of HIV-associated nephropathy in a mouse model. J Am Soc Nephrol 18: 515–527, 2007
83. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollak M, Winkler CA: APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J AmSoc Nephrol 22: 2129–2137, 2011
84. Kasembeli AN, Duarte R, Ramsay M, Mosiane P, Dickens C, Dix-Peek T, Limou S, Sezgin E, Nelson GW, Fogo AB, Goetsch S, Kopp JB, Winkler CA, Naicker S: APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans. J Am Soc Nephrol 26: 2882–2890, 2015
85. Chandra P, Kopp JB: Viruses and collapsing glomerulopathy: A brief critical review. Clin Kidney J 6: 1–5, 2013
86. Sehar N, Gobran E, Elsayegh S: Collapsing focal segmental glomerulosclerosis in a patient with acute malaria. Case Rep Med 2015: 420459, 2015
87. Martinelli R, Pereira LJ, Brito E, Rocha H: Clinical course of focal segmental glomerulosclerosis associated with hepatosplenic schistosomiasis mansoni. Nephron 69: 131–134, 1995
88. Pakasa NM, Nseka NM, Nyimi LM: Secondary collapsing glomerulopathy associated with Loa loa filariasis. Am J Kidney Dis 30: 836–839, 1997
89. Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, Kuhn JA, Dratch AD, D’Agati VD: Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12: 1164–1172, 2001
90. Dijkman HB, Weening JJ, Smeets B, Verrijp KC, van Kuppevelt TH, Assmann KK, Steenbergen EJ, Wetzels JF: Proliferating cells in HIV and pamidronate-associated collapsing focal segmental glomerulosclerosis are parietal epithelial cells. Kidney Int 70: 338–344, 2006
91. Sakarcan A, Thomas DB, O’Reilly KP, Richards RW: Lithium-induced nephrotic syndrome in a young pediatric patient. Pediatr Nephrol 17: 290–292, 2002
92. Letavernier E, Bruneval P, Mandet C, Duong Van Huyen JP, Péraldi MN, Helal I, Noël LH, Legendre C: High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2: 326–333, 2007
93. Cho ME, Hurley JK, Kopp JB: Sirolimus therapy of focal segmental glomerulosclerosis is associatedwith nephrotoxicity. Am J Kidney Dis 49: 310–317, 2007
94. Mohamed N, Goldstein J, Schiff J, John R: Collapsing glomerulopathy following anthracycline therapy. Am J Kidney Dis 61: 778–781, 2013
95. Lee VW, Harris DC: Adriamycin nephropathy: A model of focal segmental glomerulosclerosis. Nephrology (Carlton) 16: 30–38, 2011
96. Park A, Gharavi A, Kopp J, Winkler C, Pullman JA, Miner J, Suztak K: Podocyte Specific Expression of Mutant APOL1 Induces Albuminuria and Global Sclerosis in Mice, San Diego, CA, American Society of Nephrology, 2015
97. Ashley-Koch AE, Okocha EC, Garrett ME, Soldano K, De Castro LM, Jonassaint JC, Orringer EP, Eckman JR, Telen MJ: MYH9 and APOL1 are both associated with sickle cell disease nephropathy. Br J Haematol 155: 386–394, 2011
98. Nichols B, Jog P, Lee JH, Blackler D, Wilmot M, D’Agati V, Markowitz G, Kopp JB, Alper SL, Pollak MR, Friedman DJ: Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney Int 87: 332–342, 2014
99. Larsen CP, Beggs ML, Saeed M, Walker PD: Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy. J Am Soc Nephrol 24: 722–725, 2013
100. KDIGO Glomerulonephritis Work Group: KDIGO clinical practice guidelines for glomerulonephritis. Kidney Int 2[Suppl]: 139–274, 2012
101. Teeninga N, Kist-van Holthe JE, van den Akker EL, Kersten MC, Boersma E, Krabbe HG, Knoers NV, van der Heijden AJ, Koper JW, Nauta J: Genetic and in vivo determinants of glucocorticoid sensitivity in relation to clinical outcome of childhood nephrotic syndrome. Kidney Int 85: 1444–1453, 2014
102. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL; North America Nephrotic Syndrome Study Group: A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. Kidney Int 56: 2220–2226, 1999
103. Senthil Nayagam L, Ganguli A, Rathi M, Kohli HS, Gupta KL, Joshi K, Sakhuja V, Jha V: Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: A pilot study. Nephrol Dial Transplant 23: 1926–1930, 2008
104. Braun N, Schmutzler F, Lange C, Perna A, Remuzzi G, Risler T, Willis NS: Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev 3: CD003233, 2008
105. Hahn D, Hodson EM, Willis NS, Craig JC: Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 3: CD001533, 2015
106. Hodson EM, Knight JF, Willis NS, Craig JC: Corticosteroid therapy for nephrotic syndrome in children (Cochrane Review). In: The Cochrane Library, Oxford, UK, Oxford Update Software, 2003
107. Pravitsitthikul N, Willis NS, Hodson EM, Craig JC: Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev 10: CD002290, 2013
108. Beer A, Mayer G, Kronbichler A: Treatment strategies of adult primary focal segmental glomerulosclerosis: A systematic review focusing on the last two decades. BioMed Res Int 2016: 4192578, 2016
109. Hogan J, Radhakrishnan J: The treatment of idiopathic focal segmental glomerulosclerosis in adults. Adv Chronic Kidney Dis 21: 434–441, 2014
110. Meyrier A: An update on the treatment options for focal segmental glomerulosclerosis. Expert Opin Pharmacother 10: 615– 628, 2009
111. Ponticelli C, Graziani G: Current and emerging treatments for idiopathic focal and segmental glomerulosclerosis in adults. Expert Rev Clin Immunol 9: 251–261, 2013
112. Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, Pan C, Savin V, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H: Phase 1 trial of adalimumab in focal segmental glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis 55: 50–60, 2010
113. Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB: Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2: 906–913, 2007
114. Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DR, Peters H, Rota S, Remuzzi G, Rump LC, Sellin LK, Heaton JP, Streisand JB, Hard ML, Ledbetter SR, Vincenti F: A phase 1, single-dose study of fresolimumab, an anti-TGF-b antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 79: 1236–1243, 2011
115. Hari P, Bagga A, Jindal N, Srivastava RN: Treatment of focal glomerulosclerosis with pulse steroids and oral cyclophosphamide. Pediatr Nephrol 16: 901–905, 2001
116. Coppo R, Camilla R, Porcellini MG, Peruzzi L, Gianoglio B, Amore A, Daprà V, Loiacono E, Fonsato V, Dal Canton A, Esposito C, Esposito P, Tovo PA: Saquinavir in steroid-dependent and -resistant nephrotic syndrome: A pilot study. Nephrol Dial Transplant 27: 1902–1910, 2012
117. Hogan J, Bomback AS, Mehta K, Canetta PA, Rao MK, Appel GB, Radhakrishnan J, Lafayette RA: Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clin J Am Soc Nephrol 8: 2072–2081, 2013
118. Madan A, Mijovic-Das S, Stankovic A, Teehan G, Milward AS, Khastgir A: Acthar gel in the treatment of nephrotic syndrome: A multicenter retrospective case series. BMC Nephrol 17: 37, 2016
119. Lieberman KV, Pavlova-Wolf A: Adrenocorticotropic hormone therapy for the treatment of idiopathic nephrotic syndrome in children and young adults: A systematic review of early clinical studies with contemporary relevance [published online ahead of print April 16, 2016]. J Nephrol doi:10.1007/s40620-016-0308-3
120. Sgambat K, Banks M, Moudgil A: Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome. Pediatr Nephrol 28: 2131–2135, 2013
121. Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang JM, Chen HC, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke GW 3rd, Mundel P: Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 369: 2416–2423, 2013
122. Spino C, Jahnke JS, Selewski DT, Massengill S, Troost J, Gipson DS: Changing the paradigm for the treatment and development of new therapies for FSGS. Front Pediatr 4: 25, 2016
123. Mariani LH, Pendergraft WF 3rd, Kretzler M: Defining glomerular disease in mechanistic terms: Implementing an in-tegrativebiologyapproach in nephrology. Clin J Am Soc Nephrol 11: 2054–2060, 2016
124. Copelovitch L, Guttenberg M, Pollak MR, Kaplan BS: Renin-angiotensin axis blockade reduces proteinuria in pre-symptomatic patients with familial FSGS. Pediatr Nephrol 22: 1779–1784, 2007
125. Fujisaki K, Tsuruya K, Nakano T, Taniguchi M, Higashi H, Katafuchi R, Kanai H, Nakayama M, Hirakata H, Kitazono T; Impact of Combined Losartan/Hydrochlorothiazide on Proteinuria in Patients with Chronic Kidney Disease and Hypertension (ILOHA) Study Investigators: Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. Hypertens Res 37: 993–998, 2014
126. Kangovi S, Edwards M, Woloszynek S, Mitra N, Feldman H, Kaplan BS, Meyers KE: Renin-angiotensin-aldosterone system inhibitors in pediatric focal segmental glomerulosclerosis. Pediatr Nephrol 27: 813–819, 2012
127. Cheng J, Zhang X, Tian J, Li Q, Chen J: Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: A meta-analysis. Int J Clin Pract 66: 917–923, 2012
128. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 372: 547–553, 2008
129. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O’Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P; VA NEPHRON-D Investigators: Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369: 1892–1903, 2013
130. Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T; EVALUATE Study Group: Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: A double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2: 944–953, 2014
131. Shavit L, Lifschitz MD, Epstein M: Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: Current concepts and emerging treatment paradigms. Kidney Int 81: 955–968, 2012
132. Xing CY, Saleem MA, Coward RJ, Ni L, Witherden IR, Mathieson PW: Direct effects of dexamethasone on human podocytes. Kidney Int 70: 1038–1045, 2006
133. Li L, Zhang T, Diao W, Jin F, Shi L, Meng J, Liu H, Zhang J, Zeng CH, Zhang MC, Liang S, Liu Y, Zhang CY, Liu Z, Zen K: Role of myeloid-derived suppressor cells in glucocorticoid-mediated amelioration of FSGS. J Am Soc Nephrol 26: 2183–2197, 2015
134. Schmid H, Henger A, Cohen CD, Frach K, Gröne HJ, Schlöndorff D, Kretzler M: Gene expression profiles of podocyte-associated molecules as diagnostic markers in acquired proteinuric diseases. J Am Soc Nephrol 14: 2958–2966, 2003
135. Hirakawa M, Tsuruya K, Yotsueda H, Tokumoto M, Ikeda H, Katafuchi R, Fujimi S, Hirakata H, Iida M: Expression of synaptopodin and GLEPP1 as markers of steroid responsiveness in primary focal segmental glomerulosclerosis. Life Sci 79: 757– 763, 2006
136. Jafry N, Ahmed E, Mubarak M, Kazi J, Akhter F: Raised serum creatinine at presentation does not adversely affect steroid response in primary focal segmental glomerulosclerosis in adults. Nephrol Dial Transplant 27: 1101–1106, 2012
137. Fan L, Liu Q, Liao Y, Li Z, Ji Y, Yang Z, Chen J, Fu J, Zhang J, Kong Y, Fu P, Lou T, Liu Z, Yu X, Chen W: Tacrolimus is an alternative therapy option for the treatment of adult steroid-resistant nephrotic syndrome: A prospective, multicenter clinical trial. Int Urol Nephrol 45: 459–468, 2013
138. Kopp JB, Winkler CA, Zhao X, Radeva MK, Gassman JJ, D’Agati VD, Nast CC, Wei C, Reiser J, Guay-Woodford LM, Pollak MR, Hildebrandt F, Moxey-Mims M, Gipson DS, Trachtman H, Friedman AL, Kaskel FJ; FSGS-CT Study Consortium: Clinical features and histology of apolipoprotein L1-associated nephropathy in the FSGS clinical trial. J Am Soc Nephrol 26: 1443– 1448, 2015
139. Trachtman H, Vento S, Herreshoff E, Radeva M, Gassman J, Stein DT, Savin VJ, Sharma M, Reiser J, Wei C, Somers M, Srivastava T, Gipson DS: Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: Report of the font clinical trial group. BMC Nephrol 16: 111, 2015